etodolac has been researched along with Cholera Infantum in 9 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The safety profile of a new sustained-release (SR) form of etodolac was evaluated in 539 young and elderly patients with osteoarthritis or rheumatoid arthritis." | 5.07 | The safety profile of sustained-release etodolac. ( Schattenkirchner, M, 1993) |
| "Oxaprozin is an effective, long-acting anti-inflammatory analgesic, but its comparative advantages remain undefined." | 2.39 | A review of selected newer nonsteroidal anti-inflammatory drugs. ( Amadio, P; Cummings, DM, 1994) |
| " In conclusion, acute and chronic dosing of nabumetone at doses up to five times the ID25 did not cause GI damage in rats." | 2.38 | Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies. ( Spangler, RS, 1993) |
| "Etodolac is a generic nonsteroidal anti-inflammatory drug (NSAID)." | 1.32 | Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis. ( Cryer, B; Cung, A; Kazi, S; Kelly, KC; Little, BB; Roberts, KW; Sarosi, GA; Smith, HJ; Weideman, RA, 2004) |
| "The costs of treating gastroduodenal ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are shown to increase the total cost of NSAID treatment to the Assurance-Maladie, the French national health insurance system." | 1.28 | The economic consequences of NSAID-induced gastropathy: the French context. ( de Pouvourville, G, 1992) |
| " The elderly appear to be no more at risk of experiencing adverse effects than the general population." | 1.28 | An updated safety profile of etodolac in several thousand patients. ( Schattenkirchner, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (77.78) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Micklewright, R | 1 |
| Lane, S | 1 |
| Linley, W | 1 |
| McQuade, C | 1 |
| Thompson, F | 1 |
| Maskrey, N | 1 |
| Weideman, RA | 1 |
| Kelly, KC | 1 |
| Kazi, S | 1 |
| Cung, A | 1 |
| Roberts, KW | 1 |
| Smith, HJ | 1 |
| Sarosi, GA | 1 |
| Little, BB | 1 |
| Cryer, B | 1 |
| Laine, L | 1 |
| Cominelli, F | 1 |
| Sloane, R | 1 |
| Casini-Raggi, V | 1 |
| Marin-Sorensen, M | 1 |
| Weinstein, WM | 1 |
| Cummings, DM | 1 |
| Amadio, P | 1 |
| Schattenkirchner, M | 2 |
| Spangler, RS | 1 |
| de Pouvourville, G | 1 |
| Scott, DL | 1 |
3 reviews available for etodolac and Cholera Infantum
| Article | Year |
|---|---|
Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II-selective inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2003 |
A review of selected newer nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; | 1994 |
Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Dose-Response Relationship, Drug; Etodo | 1993 |
2 trials available for etodolac and Cholera Infantum
| Article | Year |
|---|---|
Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Etodolac; Gas | 1995 |
The safety profile of sustained-release etodolac.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Dose-Response Relation | 1993 |
4 other studies available for etodolac and Cholera Infantum
| Article | Year |
|---|---|
Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: a historical cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cohort Studies; Cy | 2004 |
The economic consequences of NSAID-induced gastropathy: the French context.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Cost of Illness; Diclofenac; Duodenal Ulce | 1992 |
Etodolac and the treatment of arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cartilage; Collagen; Etodolac; Gastrointestinal | 1990 |
An updated safety profile of etodolac in several thousand patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Etodolac; Gastrointestinal Diseases; Hematolog | 1990 |